Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ibrutinib 560-mg Tablet vs Imbruvica Capsules
NCT02841150Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibrutinib in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and Waldenstrom macroglobulinemia (WM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Time to Reach Maximum Concentration and 4 more. Started Jun 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02841150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02841150.